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Abstract
Background: HIV infection is associated with a high prevalence of antiphospholipid antibodies (aPL) and increased
thrombotic events but the aetiopathogenic link between the two is unclear.
Findings: Prospective single centre study from Soweto, South Africa, comparing the prevalence of aPL in highly
active anti-retroviral therapy (HAART) naïve HIV positive and negative patients presenting with Acute Coronary
Syndromes (ACS). Between March 2004 and February 2008, 30 consecutive black South African HIV patients with
ACS were compared to 30 black HIV negative patients with ACS. The HIV patients were younger (43 ± 7 vs. 54 ±
13, p = 0.004) and besides smoking (73% vs. 33%, p = 0.002) and lower HDL levels (0.8 ± 0.3 vs. 1.1 ± 0.4, p =
0.001) had fewer risk factors than the control group. HIV patients had a higher prevalence of anticardiolipin (aCL)
IgG (47% vs. 10%, p = 0.003) and anti-prothrombin (aPT) IgG antibodies (87% vs. 21%, p < 0.001) but there was no
difference in the prevalence of the antiphospholipid syndrome (44% vs. 24%, p = N/S) and aPL were not predictive
of clinical or angiographic outcomes.
Conclusions: Treatment naïve black South African HIV patients with ACS are younger with fewer traditional
coronary risk factors than HIV negative patients but have a higher prevalence and different expression of aPL
which is likely to be an epiphenomenon of the HIV infection rather than causally linked to thrombosis and the
pathogenesis of ACS.
Introduction
HIV infection is known to be associated with an
increased prevalence of aPL but the link to the antipho-
spholipid syndrome (APS) with clinical thrombosis
including myocardial infarction (MI) is tenuous [1].
Abuaf et al. [2] reported on the prevalence of aPL in
HIV infection. Anticardiolipn antibodies (aCL) were
reported to be present in 0-94%, anti-b2-glycoprotein-I
(anti-b2-GPI) in 4-47%, anti-prothrombin (aPT) in 2-
12% of patients with lupus anticoagulant (LA) found in
0-53.5%. Very few data exist on the prevalence of aPL in
black patients especially aPT and IgA aPL isotypes in
the setting of infections including HIV [3]. Loizou et al.
[3] reported on the prevalence of aPL in 100 black
South African HIV positive patients. There was a low
prevalence of anti-b2-GPI (6%), all exclusively belonging
to the IgA isotype, as well as aCL (7%), which were
mainly positive for IgG. A prevalence of 43% (mainly
IgG) aPT was found showing that the pattern of aPL in
black South Africans differs from that found in cauca-
sians [3]. Despite the unclear association between HIV,
aPL and MI, there have been case reports in the non-
HIV setting suggesting an association. A prospective
case control analysis from the Honolulu Heart Program
found that anticardiolipin antibodies, particularly the b2-
Glycoprotein-dependent variety were strongly associated
w i t ht h er i s ko fM I[ 4 ] .I nas t u d ya m o n gs u r v i v o r so f
MI, anticardiolipin antibodies were detected in 14% of
patients compared with 3% of controls [5]. The antipho-
spholipid syndrome is found more commonly in popula-
tions with MI who have a low burden of conventional
cardiovascular risk factors with little or no evidence of
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considered in patients with normal appearing infarct
related arteries [4]. We have shown that treatment-naïve
HIV positive black South African patients presenting
with acute coronary syndromes (ACS) are younger with
fewer traditional risk factors compared to HIV negative
patients and have less atherosclerotic burden but higher
thrombotic burden on angiography [6]. In a subsequent
study we showed that this group of HIV patients have
evidence of thrombophilia as evidenced by lower protein
C and higher factor VIII levels [7]. In addition, prelimin-
ary results showed a higher prevalence of aPL the signif-
icance of which is uncertain.
Study Aims
It is within this context, that we investigated the role of
aPL as a risk factor for ACS in treatment-naïve black
South Africans with minimal traditional risk factors. We
hypothesized that HIV patients with ACS, compared to
HIV negative patients, would have a higher prevalence
of aPL with a higher prevalence of the antiphospholipid
syndrome (APS) and that aPL would be causally related
to thrombosis and ACS.
Methods
Study design and patient enrollment
We conducted a prospective single centre study in the
Department of Cardiology at Chris Hani Baragwanth
Hospital, Soweto, South Africa. The protocol was
approved by the ethics committee of the University of
the Witwatersrand and adheres to the Declaration of
Helsinki. All patients gave informed consent before
study entry. Between March 2004 and February 2008, 30
consecutive black HIV patients presenting with ACS
(ACS+: HIV+ group) were enrolled. For each HIV
patient with ACS we selected the first presenting non-
HIV black patient with ACS as a case-control compara-
tor (ACS+: HIV- group). In addition a second control
group consisting of 30 asymptomatic HIV patients
matched for age, sex and ethnicity (ACS-: HIV+ group)
were recruited from the HIV clinic. ACS was defined as
either ST-elevation myocardial infarction, non ST-eleva-
tion myocardial infarction or unstable angina. Patients
were categorized as having diabetes, hypertension or
dyslipidemia when being treated chronically for these
conditions or when diagnosed with the condition on
admission. Patients were classified as having “other” cor-
onary risk factors if any of the following conditions were
present: i) Family history of premature CAD (men < 55
yrs, women < 65 yrs), ii) chronic kidney disease, iii) post
menopausal state and iv) abdominal obesity (abdominal
circumference > 102 cm in men and 88 cm in women).
Demographic data was recorded for each patient and
anthropometric measurements including weight, height,
body mass index (BMI), waist to hip ratio and abdom-
inal circumference (AC) were measured on admission
according to guidelines set out in the Interheart study
[8]. Infection with HIV was diagnosed with a standard
enzyme linked immunosorbent assay and Western blot
techniques after obtaining consent and offering pretest
counseling. In the HIV group, Plasma HIV RNA level
was determined by quantitative polymerase chain reac-
tion. CD4 count was determined by flow cytometry and
patients were staged according to the CDC staging sys-
tem [9]. Patients with ACS were managed according to
accepted guidelines set out by the European Heart Asso-
ciation [10,11] and followed up at the Chris Hani Barag-
wanath cardiac clinic.
Laboratory methods
Blood was obtained by clean venipuncture with seated
subjects and non-fasting venous blood was drawn into
plastic tubes and allowed to clot at 37 degrees and then
cetrifuged at 2500 × g for 8 minutes for sera preparation.
The serum was immediately stored at -80 degrees until
use. All sera were thawed only once in a water bath at 37
degrees for 15 minutes before testing. The analysis of
aPL was performed at Lancet Laboratories, Johannesburg.
Antiphospholipid antibodies including aCL, anti- b2-GP-
1, and aPT (IgG, IgM, IgA) were measured at baseline in
all patients and at least 12 weeks later in the ACS groups
using commercial enzyme linked immunosorbent assay
(ELISA) kits (Orgentec Diagnostika, Mainz, Germany).
The results were expressed in units, according to the
manufacturer’s instructions. IgG, IgM and IgA aCL were
expressed as U/mL. To establish normal values of aPL in
our population we used the blood samples of 100 asymp-
tomatic HIV negative black South African blood donors
matched for age and sex to the study population. Results
for each of the aPL measured were considered positive
when the optical density obtained for each patient
exceeded that of the mean value plus 2 standard devia-
tions (SD) of the 100 sera from black South African nor-
mal healthy subjects. The normal values obtained were as
follows: aCL IgG and IgA < 10 U/mL, IgM < 7 U/mL;
anti- b2-GP-1 IgG, IgA, IgM < 8 U/mL; aPT IgG, IgA,
IgM < 10 U/mL. The antiphospholipid syndrome (APS)
was diagnosed in patients with ACS who had the pre-
sence of aPL (aCL IgG/IgM and/or anti- b2-GP-1 IgG/
IgM) in titres greater than the mean plus 2SD from nor-
mal healthy subjects on two occasions at least 12 weeks
apart [12].
Stastistical analysis
Statistical analysis was performed using SAS 9.1 soft-
ware (SAS, Cary, NC, USA). Normally distributed con-
tinuous data are presented as the mean (± standard
deviation), and variables with non-Gaussian distribution
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presented as frequencies and percentages. The initial
analysis compared variables between the 3 groups using
the one way anova test for continuous variables with
normal distribution and the Kruskal Wallis test in case
of non-normal distribution. For categorical variables the
Chi square test was performed with a Fisher exact test
when necessary. Significant differences between variables
in the 3 groups was assumed at p < 0.05. Subgroup ana-
lysis with multiple pairwise comparisons was then per-
formed applying the Bonferroni correction with a p
value < 0.0166 considered significant. Univariate logistic
regression was performed to determine predictors of the
variables: aCL IgG, aPT IgG and APS: data presented as
odds ratios (OR) with 95% confidence intervals (CI).
Results
Acute Coronary Syndrome (ACS+) group
The clinical profile and prevalence of aPL in the ACS+:
HIV+ and ACS+: HIV-groups are listed in Table 1. HIV
positive patients were younger with a similar sex distribu-
tion. Besides smoking, (33% vs. 73%, p = 0.004), coronary
risk factors were higher in the ACS+: HIV- group with
more hypertension (p = 0.0001), LDL hyperlipidaemia (p =
0.003), diabetes mellitus (p = 0.03) and “other coronary
risk factors” (p = 0.0001). The ACS+: HIV+ group had
lower HDL levels (p = 0.0006) and a lower mean BMI (p =
0.008). The ACS+: HIV+ group had higher frequencies of
aCL IgG (47% vs. 10%, p = 0.003) and aPT IgG (87% vs.
21%, p < 0.001) compared to the ACS+: HIV- group.
There were no differences between groups with respect to
the other aPL frequencies. The ACS group (60 patients)
was then analysed to determine the prevalence of APS. In
the ACS+: HIV+ group, 18/30(60%) patients had aPL
results from two separate occasions, 12 weeks apart as per
diagnostic guidelines [12]. 12/30(40%) did not have repeat
testing owing to 9/30(30%) deaths and 3/30(10%) patients
lost to follow up. In the ACS+: HIV- group, 25/29(86%)
patients had aPL results from two separate occasions, 12
weeks apart with 4/29(14%) patients dying prior to repeat
testing. The diagnostic criteria for APS were met in 8/18
(44%) HIV patients vs. 6/25(24%) HIV negative patients, p
= 0.28. In the ACS+: HIV+ group, 7/8(88%) had aCL IgG
antibodies, 1/8(13%) aCL IgM, 6/8(75%) anti- b2-GP-1
IgG and 1/8(13%) anti- b2-GP-1IgM. 5/8(63%) patients
had the presence of both aCL IgG and anti- b2-GP-1IgG
antibodies. In the ACS+: HIV- group, 3/6(50%) had aCL
IgG antibodies, 1/6(17%) aCL IgM and 4/6(67%) anti- b2-
GP-1IgG. 2/6(33%) had the presence of both aCL IgG and
anti- b2-GP-1IgG antibodies.
HIV (HIV+) group
The clinical profile and prevalence of aPL in the ACS+:
HIV+ and ACS-: HIV+ groups are listed in Table 2.
The ACS+: HIV+ and ACS-: HIV+ groups were well
matched with respect to age, sex and viral load. The
ACS+: HIV+ group were less immunocompromised as
evidenced by higher CD4 counts (p = 0.013) and less
patients with AIDS defining criteria (p = 0.01) which
were all based on a CD4 count < 200 cells/ml
3.T h e r e
were no opportunistic infections or HIV related malig-
nancies in the ACS+: HIV+ group and 18/30(60%)
patients had early disease being classified as either stage
A1 or A2 [9]. In the ACS-: HIV+ group, 21/30(70%)
patients had AIDS, 18/30(60%) due to a CD4 count <
200 cells/ml
3 and 3/30(10%) patients with either oppur-
tunistic infections or AIDS related malignancies: 1/30
(3%) patient having active pulmonary Tuberculosis, 1/30
(30%) with cutaneous Kaposi’s Sarcoma and 1/30(3%)
with a Non-Hodgkins Lymphoma. 6/30(20%) had early
disease (stage A1 or A2). In terms of coronary risk fac-
tors, there were more smokers in the ACS+: HIV+
Table 1 ACS Group: Clinical profile and aPL prevalence
ACS+: HIV+ ACS+: HIV- p value
Demographic Profile:
Black African n(%) 30(100) 30(100) 1.0
Mean Age (years) 43 ± 7 54 ± 13 < 0.001
Men (%) 20(67) 18(60) N/S
Coronary risk factors n(%):
Smoking 22(73) 10(33) 0.004
Diabetes Mellitus 1(3) 7(23) 0.05
Hypertension 7(23) 23(77) < 0.001
Total cholesterol (mmol/l) 3.6 ± 1.0 4.6 ± 1.4 0.003
LDL cholesterol (mmol/l) 2.2 ± 0.9 3.0 ± 1.2 0.003
HDL cholesterol (mmol/l) 0.8 ± 0.3 1.1 ± 0.4 < 0.001
Triglycerides (mmol/l) 1.4 ± 0.8 1.1+/-0.4 N/S
BMI (kg/m
2) 25 ± 5 28 ± 5 0.008
Other coronary risk factors 2(7) 16(53) < 0.001
Baseline aPL frequencies(%):
Blood samples n(%) 30(100) 29(97)* N/S
Anticardiolipin (IgG) 14(47) 3(10) 0.003
Anticardiolipin (IgM) 3(10) 1(3) N/S
Anticardiolipin (IgA) 0(0) 3(10) N/S
Beta-2 Glycoprotein (IgG) 11(37) 6(21) N/S
Beta-2 Glycoprotein (IgM) 3(10) 0(0) N/S
Beta-2 Glycoprotein (IgA) 7(23) 12(41) N/S
Anti-Prothrombin (IgG) 26(87) 6(21) < 0.001
Anti-Prothrombin (IgM) 2(7) 0(0) N/S
Anti-Prothrombin (IgA) 2(7) 1(3) N/S
Antiphospholipid syndrome (%): 8/18(44) 6/25(24) N/S
Legend: Data are presented as the mean ± standard deviation or proportions
Key: BMI = body mass index
aPL = antiphospholipid antibody
* 1 patient not analysed due to an inadequate blood sample
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(p = 0.011) compared to the ACS-: HIV+ group. There
were no significant differences between the groups with
respect to aPL frequencies but analysis of the actual aPL
titres revealed higher levels of b2-GP-1 IgM [3.0(1.6-
10.2) vs. 2.1(1.3-15.3), p = 0.007] in the ACS-: HIV+
group compared to the ACS+: HIV+ as well as aPT IgG
[20.2(9.3-165.1) vs. 14.4(7.5-40.2), p = 0.0008], aPT IgM
[4.8(1.3-9.4) vs. 3.1(1.4-30.9), p = 0.012] and aPT IgA
[5.8(3.3-17.3) vs. 4.6(3.0-18.2), p = 0.015]. On univariate
logistic regression, HIV infection was predictive of the
presence of aCL IgG (OR 2.94, CI 1.60-5.40) and aPT
IgG antibodies (OR 16.07, CI 5.38-49.94) but did not
predict APS (OR 2.53, CI 0.69-9.36). The presence of
aPL’s (aCL IgG, aPT IgG) and APS did not predict any
of the clinical or angiographic outcomes in the study
including markers of atherosclerotic and thrombotic
burden.
Discussion
HIV infection is known to be associated with increased
frequencies of aPL [13] and the antiphospholipid syn-
drome is found more commonly in populations with
ACS who have a low burden of conventional cardiovas-
cular risk factors with little or no evidence of athero-
sclerotic disease [4] such as our HIV cohort. No data
Table 2 HIV group: Clinical profile and aPL prevalence
ACS+: HIV+ ACS-: HIV+ p value
Demographic Profile:
Black African n(%) 30(100) 30(100) 1.0
Mean Age (years) 43 ± 7 41 ± 8 N/S
Men (%) 20(67) 19(63) N/S
HIV related factors:
CD4(cells/mm
3) median(range) 230 (30 -1356) 125 (6-1041) 0.013
Viral load (RNA copies/ml) median(range) 29000 (25 - 7 × 10
5) 54000(25-11 × 105) N/S
AIDS defining criteria n(%) 11(37) 21(70) 0.01
Current oppurtunistic infection 0 1(3) N/S
HIV related malignancies 0 2(7) N/S
Coronary risk factors n(%):
Smoking 22(73) 11(37) 0.003
Diabetes Mellitus 1(3) 0(0) N/S
Hypertension 7(23) 2(7) N/S
Total cholesterol (mmol/l) 3.6 ± 1.0 3.7+/-0.8 N/S
LDL cholesterol (mmol/l) 2.2 ± 0.9 2.0 ± 0.5 N/S
HDL cholesterol (mmol/l) 0.8 ± 0.3 1.0 ± 0.5 0.011
Triglycerides (mmol/l) 1.4 ± 0.8 1.4+/-0.8 N/S
BMI (kg/m
2) 25 ± 5 21 ± 4 0.003
Other coronary risk factors 2(7) 0(0) N/S
Baseline aPL frequencies (%):
Blood samples n(%) 30(100) 30(100) 1.0
Anticardiolipin (IgG) 14/30(47) 17/30(57) N/S
Anticardiolipin (IgM) 3/30(10) 4/30(13) N/S
Anticardiolipin (IgA) 0/30(0) 0/30(0) N/S
Beta-2 Glycoprotein (IgG) 11/30(37) 10/30(33) N/S
Beta-2 Glycoprotein (IgM) 3/30(10) 2/30(7) N/S
Beta-2 Glycoprotein (IgA) 7/30(23) 8/30(27) N/S
Anti-Prothrombin (IgG) 26/30(87) 29/30(97) N/S
Anti-Prothrombin (IgM) 2/30(7) 0/30(0) N/S
Anti-Prothrombin (IgA) 2/30(7) 3/30(10) N/S
Legend: Data are presented as the mean ± standard deviation or proportions
Key: BMI = body mass index
aPL = antiphospholipid antibody
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cal correlates in HAART-naïve HIV patients. We took
the almost unique opportunity to study a HAART-naïve
population thus negating the effects of HAART on
thrombotic risk. Firstly, when comparing the ACS+:
HIV+ group and the ACS+: HIV- group, consistent
with previously published data, the HIV group were
younger in age, predominantly male, with a higher per-
centage of cigarette smokers and lower HDL levels [14].
Besides smoking, there were less traditional risk factors
for ACS in the ACS+: HIV+ group. With respect to
aPL frequencies in the ACS group, significant differ-
ences were found with HIV patients having higher fre-
quencies of aCL IgG and aPT IgG antibodies. The
incidence of APS was, however, similar in both groups.
What is the significance of these findings? The exact
role of aPL in the aetiopathogenesis of thrombosis in
HIV infected patients is controversial. Despite the find-
ings of high aPL frequencies [2] and case reports of
APS in HIV patients, antiphospholipid antibodies often
present in infectious diseases are not usually associated
with thrombotic complications [3]. In order to address
the question of significance of the aPL findings in our
HIV patients with ACS, we looked at a similar HIV
group matched for age, sex and degree of immunosup-
pression (ACS-: HIV+ group). The ACS+: HIV+ group,
had a different pattern of aPL expression compared to
recent studies investigating a predominantly caucasian
population which reported aCL to be positive in 36-
88%, anti- b2-GP-1 in 4-27%, and aPT in 2-12% of
patients [13,15-17]. In keeping with the study by Loizou
et al [3] we found a high prevalence of aPT IgG antibo-
dies in our black HIV cohort with 87% in the ACS+:
HIV+ group and 97% in the ACS-: HIV+ group. The
rates of aCL and anti- b2-GP-1 antibodies seen in our
black HIV population were similar to those described in
the recent studies on Caucasian patients [13,15-17].
Comparing the aPL frequencies within the HIV group,
there were no statistically significant differences
between the ACS+: HIV+ and ACS-: HIV+ groups but
analysis of the actual aPL titres revealed higher levels of
b2-GP-1 IgM as well as aPT (IgG, IgM, IgA) in the
ACS-: HIV+ group possibly due to a greater degree of
immunosuppresion and immune dysregulation [3], sug-
gesting that the higher frequencies of aPL seen in HIV
patients are an epiphenomenon of HIV infection rather
than causally linked to thrombotic events. The aPL seen
in HIV patients could be induced by disturbances in
regulation of cellular and humoral immunity, as a sec-
ondary consequence of HIV infection. Alternatively,
their induction might result from the exposure of cell
wall phospholipids as a consequence of damaged body
cells resulting from the HIV-related inflammatory
milieu [3]. Several limitations of the study require
comment. Although the study constitutes one of the
largest prospective analyses on treatment-naïve patients
with ACS, the sample size in each group was relatively
small resulting in a lack of power to detect small differ-
ences between the groups which may have been signifi-
cant. In addition, not all patients had repeat testing at
12 weeks which would have influenced the reported
incidence of APS in the patients who had thrombotic
events. Wherever possible, however, we have adhered to
the recently published STROBE guidelines in our
reporting of study data [18].
Conclusions
Treatment-naïve HIV patients presenting with ACS have
different risk factors and clinical features compared to
the HIV negative population as well as a higher preva-
lence and different pattern of aPL expression. It is unli-
kely that aPL in this group of patients are causally
linked to ACS and are more likely an epiphenomenon
of HIV infection. It is possible that the pathogenesis of
thrombosis in these patients is multifactorial with the
interaction of conventional risk factors and other HIV-
specific coagulation abnormalities which warrants
further study. To this extent smoking is an important
modifiable risk factor and should be an important target
for cardiovascular risk reduction. Routine screening for
antiphospholipid antibodies in HIV patients presenting
with ACS and minimal risk factors cannot be justified
based on these findings.
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